{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.1","value":"70.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"416"}],"units":"Participants"}],"title":"Cycle 1 Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.2","value":"111"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"384"}],"units":"Participants"}],"title":"Cycle 2 Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.8","value":"134"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"}],"units":"Participants"}],"title":"Cycle 3 Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"93.7","value":"218"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"257"}],"units":"Participants"}],"title":"Cycle 7 Day 21"}],"denoms":[{"counts":[{"groupId":"OG000","value":"465"}],"units":"Participants"}],"description":"Predose samples will be collected on the same day of treatment administration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"}],"paramType":"MEAN","populationDescription":"The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 21, Cycle 2 Day 21, Cycle 3 Day 21, and Cycle 7 Day 21 (Cycle length = 21 days)","title":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel","type":"SECONDARY","unitOfMeasure":"mcg/mL"}